• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ: ENVB )

0.3250 -0.0034 (-1.04%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 202,107
Open 0.3143
Bid (Size) 0.3250 (3)
Ask (Size) 0.3495 (3)
Prev. Close 0.3284
Today's Range 0.3130 - 0.3366
52wk Range 0.3036 - 2.920
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds
December 02, 2024
From Enveric Biosciences
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 27, 2024
Via Benzinga

Performance

YTD
-74.21%
-74.21%
1 Month
-3.53%
-3.53%
3 Month
-29.36%
-29.36%
6 Month
-51.42%
-51.42%
1 Year
-75.38%
-75.38%

More News

Read More
Enveric Biosciences Advances Non-Hallucinogenic DMT Analog Drug With Promising Preclinical Results
November 25, 2024
Via Benzinga
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior
November 25, 2024
From Enveric Biosciences, Inc.
Via Business Wire
Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket
November 19, 2024
Via Benzinga
Enveric Biosciences Trims Losses, Eyes Key Drug Approval For Difficult-To-Treat Mental Health Disorders
November 18, 2024
Via Benzinga
Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results
November 14, 2024
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Out-Licenses Key Program To MycoMedica In $62M Deal
November 12, 2024
Via Benzinga
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
November 12, 2024
From Enveric Biosciences, Inc.
Via Business Wire
Enveric Biosciences Announces Broad Range of Patent Issuances
November 04, 2024
From Enveric Biosciences
Via Business Wire
Enveric Biosciences Expands Mental Health Patent Portfolio With 5 New Additions
November 04, 2024
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
12 Health Care Stocks Moving In Wednesday's After-Market Session
October 23, 2024
Via Benzinga
Enveric Biosciences Advances Testing Of Its Non-Hallucinogenic Psychedelic
October 15, 2024
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 15, 2024
Via Benzinga
Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003
October 15, 2024
From Enveric Biosciences
Via Business Wire
Psychedelics 2.0: Companies Explore Safer, More Targeted Therapies
October 04, 2024
Via Benzinga
Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop
September 26, 2024
From Enveric Biosciences
Via Business Wire
Non-Hallucinogenic Psychedelic Treatment For Anxiety And Depression In Pre-Clinical Models: Enveric Biosciences' Breakthrough Research
September 25, 2024
Via Benzinga
Enveric Biosciences Presents Data on Lead Product Candidate, EB-003, at 7th Neuropsychiatric Drug Summit
September 25, 2024
From Enveric Biosciences
Via Business Wire
Enveric Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 04, 2024
From Enveric Biosciences
Via Business Wire
Aries Science & Technology and Enveric Biosciences Announce Issuance of Key US Patent Under Aries’ License for Treatment of Radiation Dermatitis and Other Conditions
August 13, 2024
From Enveric Biosciences
Via Business Wire
ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q2 2024
August 12, 2024
Via InvestorPlace
Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results
August 12, 2024
From Enveric Biosciences
Via Business Wire
Why Merck Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 30, 2024
Via Benzinga
Why Is Imunon (IMNN) Stock Up 259% Today?
July 30, 2024
Via InvestorPlace
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap